Managing Myelofibrosis-Associated Thrombocytopenia
- Author
- ReachMD
- Published
- Fri 19 Jul 2024
- Episode Link
- http://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
